Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Active, not recruiting · NCT05864534 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, gliosarcoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-29 | NCT05864534 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Agenus Inc. | 23 |
| CarThera | 5 |
| Northwestern University | 381 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern University | Chicago | United States | 727 |